Industry Insights

  1. eSource Is Here: What To Do Today To Ensure Success Tomorrow

    What can organizations – both in research and in technology – do to help define that future?

  2. CRO Consolidations – A Boon for Pharma?

    CRO mergers affect the agility and speed of operations and may hamper efforts to bring in new technologies but at the same time can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.

  3. Collaboration Is The Secret To Successful Outsourcing

    Best practices to ensure a successful sponsor-CRO collaboration

  4. GDPR: New Considerations And Shared Experiences For Life Sciences Companies

    Life science industry peers can share knowledge and strategies as they make adjustments and strive to establish new best practices and navigate necessary system changes.

  5. Integrating IBC And IRB Review—A New Paradigm

    Avoid additional work and expense by mastering dual IRB and IBC review.

  6. Don’t Let Burdensome Site Payment Processes Undermine Your Study Performance

    CROs & Sponsors:  Have we overcome the limitations of early site payment solutions? Learn how a Site Payment Advisory Group helped improve site payment technology for all stakeholders.

  7. 3 Signs Your EDC Is Fit for Today’s Clinical Trials

    Provide EDC users the benefits that are essential to successful clinical data management.

  8. Clinical Research Site Payment Study

    Study helps further understand the current processes related to reconciling payments at research sites, the level of satisfaction at research sites around receivables, as well as the impact that reconciling payments from sponsors / CROs has on the site’s ability to conduct a clinical trial.

  9. Investigator Site Turnover: The Importance Of CRO Support

    How to offer superior value-add by enhancing a site’s clinical trial experience for improved outcomes, strengthening the relationship and positioning sites for future trial success.

  10. FDA Published Guidance For Payment To Clinical Trial Study Participants

    FDA guidance document specifically emphasizes the importance of analyzing study participant payments in order to reduce the likelihood of coercion.